摘要
抗耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)感染和对多重耐药金黄色葡萄球菌的治疗一直是临床的严峻挑战。头孢洛林、达巴万星、特地唑胺和奥利万星是美国FDA最新批准的用于抗MRSA感染的药物,本文将对它们的结构特点与作用机制、体内外抗菌活性、不良反应以及临床应用与未来发展进行综述,并着重分析其特性和优劣势。
Anti-MRSA infection and the treatment of multiple drug-resistant Staphylococcus aureus has always been a serious clinical challenge. Ceftaroline, dalbavancin, tedizolid and oritavancin are the latest drugs approved by the FDA for the treatment of MRSA infection. In this article, we will review their structure characteristics and mechanism of action, in vitro and in vivo antibacterial activity, adverse reactions, clinical application and future development, and we will focus on its characteristics, advantages and disadvantages of these new durgs.
出处
《国外医药（抗生素分册）》
CAS
2017年第4期166-172,178,共8页
World Notes on Antibiotics
基金
广东省重大科技专项(2013A022100035)
